Literature DB >> 1737645

Endothelium-derived contracting factors.

T F Lüscher1, C M Boulanger, Y Dohi, Z H Yang.   

Abstract

The endothelium not only mediates relaxation but is a source of contracting factors. Endothelium-dependent contractions are elicited by physical and chemical stimuli (i.e., hypoxia, pressure, and stretch) and autacoids, local and circulating hormones. The mechanism of endothelium-dependent contractions to hypoxia involves withdrawal of nitric oxide. The endothelial cyclooxygenase pathway can produce thromboxane A2, prostaglandin H2, and superoxide anions. The peptide endothelin is a potent contracting factor; its production is stimulated by vasopressor hormones, platelet-derived factors, coagulation products, and cytokines, whereas endothelium-derived nitric oxide, prostacyclin, and a smooth muscle cell-derived inhibitory factor reduce endothelin production. In hypertension, the release of cyclooxygenase-dependent endothelium-derived contracting factors to stretch, acetylcholine, and platelet-derived products is augmented. Vascular endothelin production in hypertension remains controversial but appears mostly normal; it is augmented in the presence of vascular disease or renal insufficiency. The endothelium-dependent inhibition of endothelin-induced contractions is reduced in hypertension while the reactivity of vascular smooth muscle may be normal, increased, or reduced. The potentiating effects of low concentrations of endothelin on contractions to norepinephrine are augmented with aging and hypertension. In atherosclerosis, the production of the cyclooxygenase-dependent endothelium-derived contracting factors and endothelin is enhanced. Thus, endothelium-derived contracting factors can profoundly affect vascular tone and counteract relaxing factors produced within the endothelium. In hypertension and atherosclerosis, the role of contracting factors appears to become more dominant, leading to an imbalance of endothelium-dependent vascular regulation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737645     DOI: 10.1161/01.hyp.19.2.117

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  41 in total

1.  Endothelium derived relaxing factor/nitric oxide.

Authors:  G Blaise
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

Review 2.  Endothelial regulation of vascular tone.

Authors:  P Vallance
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

3.  Dietary salt blunts vasodilation by stimulating epithelial sodium channels in endothelial cells from salt-sensitive Dahl rats.

Authors:  Zi-Rui Wang; Hui-Bin Liu; Ying-Ying Sun; Qing-Qing Hu; Yu-Xia Li; Wei-Wan Zheng; Chang-Jiang Yu; Xin-Yuan Li; Ming-Ming Wu; Bin-Lin Song; Jian-Jun Mu; Zu-Yi Yuan; Zhi-Ren Zhang; He-Ping Ma
Journal:  Br J Pharmacol       Date:  2017-05-10       Impact factor: 8.739

4.  Development of vascular smooth muscle contractility by endothelium-derived transforming growth factor β proteins.

Authors:  Chiwaka Kimura; Shuhei Konishi; Maki Hasegawa; Masahiro Oike
Journal:  Pflugers Arch       Date:  2013-07-26       Impact factor: 3.657

5.  Role of the M3 muscarinic acetylcholine receptor subtype in murine ophthalmic arteries after endothelial removal.

Authors:  Adrian Gericke; Andreas Steege; Caroline Manicam; Tobias Böhmer; Jürgen Wess; Norbert Pfeiffer
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-29       Impact factor: 4.799

6.  TP receptor antagonists (TXRAs): expensive irrelevance or wonder drugs strangled at birth?

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

Review 7.  The renin-angiotensin-aldosterone system and cardiac ischaemia.

Authors:  H Ikram
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

8.  Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis.

Authors:  Pierre-François Lesault; Laurent Boyer; Gabriel Pelle; Ala Covali-Noroc; Dominique Rideau; Servais Akakpo; Emmanuel Teiger; Jean-Luc Dubois-Randé; Serge Adnot
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

Review 9.  Is reversal of endothelial dysfunction still an attractive target in modern cardiology?

Authors:  Ify Mordi; Nikolaos Tzemos
Journal:  World J Cardiol       Date:  2014-08-26

10.  Late chronic catechin antioxidant treatment is deleterious to the endothelial function in aging mice with established atherosclerosis.

Authors:  Marie-Eve Gendron; Jean-François Théorêt; Aida M Mamarbachi; Annick Drouin; Albert Nguyen; Virginie Bolduc; Nathalie Thorin-Trescases; Yahye Merhi; Eric Thorin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.